Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross‐disciplinary translational hypothesis

@article{Norris2020ConspicuityOP,
  title={Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross‐disciplinary translational hypothesis},
  author={Joseph M. Norris and Benjamin S. Simpson and Alex Freeman and Alex P. Kirkham and Hayley C. Whitaker and Mark Emberton},
  journal={The FASEB Journal},
  year={2020},
  volume={34},
  pages={14150 - 14159}
}
Pre‐biopsy multiparametric magnetic resonance imaging (mpMRI) has transformed the risk stratification and diagnostic approach for suspected prostate cancer. The majority of clinically significant prostate cancers are visible on pre‐biopsy mpMRI, however, there are a subset of significant tumors that are not detected by mpMRI. The radiobiological mechanisms underpinning mpMRI‐visibility and invisibility of these cancers remain uncertain. Emerging evidence suggests that mpMRI‐visible tumors are… 

Relationship of prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: a protocol for a systematic review and meta-analysis

TLDR
A systematic review and meta-analysis of MRI performance between different locations within the prostate in men with existing or suspected prostate cancer will help clarify mechanisms that underpin whether a tumour is visible, and the prognostic implications of the findings.

Tumour microenvironment and focal therapy for prostate cancer

TLDR
A better understanding of TME has the potential to reliably elucidate PCa heterogeneity and assign a prognostic profile in accordance with prostate tumours foci, and the joint contribution of biomarkers derived from both tumour and TME compartments may improve patient selection for FT by accurately stratifying disease aggressivity according to the characteristics of tumour foci.

The Prognostic Value of PI-RADS Score in CyberKnife Ultra-Hypofractionated Radiotherapy for Localized Prostate Cancer

TLDR
PI-RADS 5 and the size of the target lesion are important prognostic factors in early-stage PCa patients and should be considered as an adverse prognostic measure for patients undergoing early treatment such as radiation or focal therapy.

Assessing the impact of MRI based diagnostics on pre-treatment disease classification and prognostic model performance in men diagnosed with new prostate cancer from an unscreened population

TLDR
MRI guided diagnostics does change pre-treatment risk groups assignments but the overall prognostic impact appears modest in men referred for suspected prostate cancer from an unscreened population.

Does modern active surveillance offer an opportunity for new therapeutic strategies in early prostate cancer?

National and international guidelines endorse AS as the preferred method of managing men with low-risk disease and as an option for selected men with intermediate-risk features (1). For this latter

NEW STABILITY INDICATING METHOD DEVELOPMENT AND VALIDATION OF CAPECITABINE AND DOCETAXEL IN BULK AND PHARMACEUTICAL DOSAGE FORM BY USING RP-HPLC

Objective: The current investigation was pointed at developing and progressively validating novel, simple, responsive and stable RP-HPLC method for the measurement of active pharmaceutical

References

SHOWING 1-10 OF 67 REFERENCES

Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock

TLDR
This finding is important, given that in PROMIS, no men with overall Gleason score 4 + 3 had negative pre-biopsy mpMRI, indicating that actually mpMRI may identify all truly significant cancer (if SPCG-4 is used to guide the authors' threshold).

Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis

TLDR
A protocol for the first systematic review and novel bioinformatic analysis of the genomic basis of prostate cancer conspicuity on multiparametric MRI is described, to ensure methodological rigour.

Prostate cancer visibility on multiparametric magnetic resonance imaging: high Gleason grade and increased tumour volume are not the only important histopathological features

TLDR
Histopathological features (beyond grade and volume) associated with tumour conspicuity on mpMRI are explored, which mean small, low-grade cancers can be avoided, whilst high-risk tumours can be detected.

Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer

TLDR
Investigation of plausible histopathological factors that affect the detectability of prostate cancers on multiparametric magnetic resonance imaging found changes in cancer cells, stroma, and luminal spaces could be considered one of the best predictors to clinical, in vivo MRI-detectable of prostate cancer.

Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer

TLDR
Imaging features of mpMRI and 68Ga-PSMA-PET/CT can guide to the genomically most aggressive lesion of a PCa, and radiogenomics may help to better differentiate between indolent and aggressive PCa in the future.
...